Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
Abstract Interferon‐α2 reduces elevated blood cell counts and splenomegaly in patients with myeloproliferative neoplasms (MPN) and may restore polyclonal hematopoiesis. Its use is limited by inflammation‐mediated toxicity, leading to treatment discontinuation in 10‐30% of patients. Ruxolitinib, a po...
Saved in:
Main Authors: | Stine Ulrik Mikkelsen, Lasse Kjær, Mads Emil Bjørn, Trine Alma Knudsen, Anders Lindholm Sørensen, Christen Bertel Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Daniel El Fassi, Torben A. Kruse, Thomas Stauffer Larsen, Hans Torben Mourits‐Andersen, Claus Henrik Nielsen, Niels Pallisgaard, Mads Thomassen, Vibe Skov, Hans Carl Hasselbalch |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-08-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.1619 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case report: Successful use of ruxolitinib to treat interstitial pneumonia as an unusual primary presentation in primary myelofibrosis—two birds with one stone
by: Pingping Xiao, et al.
Published: (2024-11-01) -
Treatment Strategies Used in Treating Myelofibrosis: State of the Art
by: Massimo Martino, et al.
Published: (2024-10-01) -
Successful treatment of pyoderma gangrenosum complicated by JAK2V617F mutation-positive myelofibrosis with adalimumab and systemic steroid
by: Kyohei Shibuta, et al.
Published: (2025-01-01) -
Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab
by: Efterpi Zafiriou, et al.
Published: (2025-01-01) -
Determining level of endogenous serum erythropoietin for differential diagnosis of polycythemia vera and symptomatic polycythemia
by: Kostyukevych O.M.
Published: (2013-06-01)